PURPOSE: To analyze the effect of the daily use of brimonidine tartrate 0.15% on the dark-adapted pupil diameter in dark brown irides. METHODS: Twenty-five healthy volunteers administered brimonidine tartrate 0.15% to their right eyes once daily for 3 weeks. Infrared digital photographs of the pupil were taken before administration and 1 hour and 4 hours after administration after dark adaptation (at <0.1 lux ambient illumination for 5 minutes). The diameters of both pupils were measured on the first day, on administration days 7 and 21, and on washout day 7. RESULTS: Four hours after the first administration, pupils showed a decrease of 0.95+/-0.74 mm, 1.03+/-0.94 mm, 0.61+/-0.85 mm on the first day, administration day 7, and administration day 21, respectively (p<0.01), compared with baseline data. The anti-mydriatic effect of brimonidine was sustained for 3 weeks, but the proportions of the eyes showing a reduction in pupil diameter by 0.5 mm or more were 84%, 76%, 68%, and 52% at 4 hours on the first day, administration days 7 and 21, and washout day 7, respectively. CONCLUSIONS: The anti-mydriatic effect of the daily use of brimonidine 0.15% on dark brown irides in a scotopic condition is maintained during the instillation period but has a tendency to fade over time. This point should be considered when using this compound as a miotic agent.
Dark Adaptation ; Eye ; Lighting ; Pupil ; Quinoxalines ; Brimonidine Tartrate

PURPOSE: To investigate the effects of 0.15% brimonidine tartrate ophthalmic solution spray on the luminal changes in the nasolacrimal excretory system. METHODS: A prospective study was performed on 52 eyes in 26 patients complaining of epiphora in both eyes. The randomly-assigned 26 test eyes (cases) received spray of the solution through the nasal cavity, and the other 26 eyes (controls) were irrigated with the same drug through the inferior calnaliculus. Dacryocystography was then performed to observe the luminal changes jn the nasolacrimal excretory system, patient symptoms and physiologic drainage functions. RESULTS: The changes in lumen width of the nasolacrimal duct (NLD) were noted, and the changes in lumen width of the lacrimal sac were not significant in either mode. The upper and middle parts of the NLD were widened more in the irrigation group, and the lower part of the NLD was widened more in the spray group. Though there was no significant difference in the physiologic drainage functions, the patients in both groups reported reduced symptoms. CONCLUSIONS: Brimonidine tartrate spray altered the width of the NLD and improved the subjective symptoms of patients. Therefore, the spray can be applied in functional NLD obstruction patients before the surgical procedure.
Drainage ; Eye ; Humans ; Lacrimal Apparatus Diseases ; Nasal Cavity ; Nasolacrimal Duct ; Phenobarbital ; Prospective Studies ; Quinoxalines ; Brimonidine Tartrate

BACKGROUND: Mechanical allodynia is generally resulted from nerve damage by direct injury or inflammation. Thus, this study was designed to compare the antiallodynic effect of morphine, brimonidine and rilmenidine in two models of neuropathic pain, that is, induced by nerve ligation and neuritis. METHODS: Rats were prepared with tight ligation of the L5/L6 spinal nerves (SNL group) or with Freund's complete adjuvant (FCA) administration evoked sciatic inflammatory neuritis (SIN group). Antiallodynic effects by intrathecal morphine, brimonidine and rilmenidine were measured by applying von Frey filaments to the lesioned hind paw. Thresholds for withdrawal response were assessed and converted to % MPE to obtain an effective dose 50% (ED 50) and a dose response curve. RESULTS: Either SNL group or SIN group showed marked mechanical allodynia in the lesioned hind paw. Antiallodynic effects of morphine were different between two groups. That is ED 50 was 0.16 microgram (SIN) and 8.12 microgram (SNL), and dose response curve of the SIN group shifted left from that of the SNL group. The difference between SIN and SNL groups was statistically significant (P < 0.05). With the brimonidine or rilmenidine administration, ED 50 s were 0.12 microgram (SNL) and 0.37 microgram (SIN) and 2.16 microgram (SIN) and 11.46 microgram (SNL), respectively. And the shift to left of dose response curve from the SNL group is more prominent with rilmenidine administration. CONCLUSIONS: These results suggest morphine and rilmenidine showed a better effect on reducing the mechanical allodynia induced by FCA administration.
Animals ; Hyperalgesia ; Inflammation ; Ligation ; Morphine ; Neuralgia ; Neuritis ; Oxazoles ; Quinoxalines ; Rats ; Spinal Nerves ; Brimonidine Tartrate

PURPOSE: The purpose of this study was to investigate the prophylactic effect of brimonidine 0.15% on intraocular pressure (IOP) elevation and the risk factors for its elevation after intravitreal triamcinolone acetonide injection (IVTA). METHODS: A prospective, randomized clinical trial was conducted on 67 eyes of 64 patients undergoing IVTA. Eyes were randomly divided into two groups, those which had used brimonidine 0.15% (40 eyes) and those which had not used it (27 eyes). IOP was measured preoperatively, at one week, and monthly until six months post-injection in each group. RESULTS: The mean post.injection IOP at one week was 11.93+/-3.36 mmHg for the group that had used brimonidine and 13.58+/-3.25 mmHg for the group that had not used it. The difference between the two groups was statistically significant at one week (p=0.049), but others were not statistically significant. An elevation in the IOP of more than 22 mmHg was seen in 8 eyes (20%) in the group using brimonidine and in 7 eyes (25.9%) in the group not using brimonidine. There was no difference in the incidence of IOP elevation between the two groups. CONCLUSIONS: Prophylactic use of brimonidine 0.15% will prevent sudden IOP elevation and will, therefore, prevent damage to the retina and optic nerve. However, in the long term, there is no prophylactic effect of brimonidine 0.15% on IOP elevation because there was no difference in the incidence of IOP elevation of more than 22 mmHg between the two groups.
Eye ; Humans ; Incidence ; Intraocular Pressure ; Intravitreal Injections ; Optic Nerve ; Prospective Studies ; Quinoxalines ; Retina ; Risk Factors ; Triamcinolone ; Triamcinolone Acetonide ; Brimonidine Tartrate

BACKGROUND: Varenicline is recently known as smoking cessation medicine has no results of researches conducted in the actual practice settings except for incipient clinical trials. This research attempted to analyze the factors for smoking cessation by using Varenicline prescribed in the family clinic, and the efficacy of Varenicline. METHODS: Brief smoking cessation education was conducted on 140 people who visited the Department of Family Medicine at Dankook University and Varenicline was prescribed for them. This research checked whether smoking was stopped or not after six months and analyzed the factors for succeeding in smoking cessation. RESULTS: Varenicline was prescribed for the 140 people. After six months, 46 smokers were successful in smoking cessation, representing the rate of success of 35.4%, and after 12 months, 31 people of 83 people were successful in smoking cessation, representing the rate of success of 37.3%. The group less smoke than 24.3 cigarettes/day (the average daily smoking amount) has higher quit rate than the group more smoke than 24.3 by 4.9 times. The group takes Varenicline longer than 26.7 days (the average Varenicline dosage period) has higher quit rate than the group takes Varenicline shorter than 26.7 by 4 times. Smoking-cessation rate was 4.5 times when trying to stop smoking by the doctor's recommendation. It was higher than when trying to stop smoking by self-determination. In the multivariate analysis, there were significant relationships in daily smoking amount, dosage and period of Varenicline, and motivation of visits. CONCLUSION: Varenicline is one of the useful medication for quitting smoking in family practice setting. Better compliance of medicine shows better quitting rate.
Benzazepines ; Compliance ; Family Practice ; Humans ; Motivation ; Multivariate Analysis ; Quinoxalines ; Smoke ; Smoking ; Smoking Cessation ; Varenicline

Craving has been well known to be the most important clinical phenomenon in smoking cessation treatment and one that physicians always encounter. For successful and prolonged abstinence, understanding, evaluation, and management of craving are essential. The concept and definition of craving is still under debate, although its importance, relevance, and role in smoking relapse is evident. There are two types of craving, 'abstinence-induced craving' and 'cue-induced craving' according to time dynamic and causes. The evaluation of craving mainly depends on self-reported measures in the clinical field. Pharmacological treatments such as the nicotine patch, bupropion, and varenicline are effective for abstinence-induced craving. Psychosocial treatment and a few pharmacological agents such as nicotine gum and lozenges are useful for reducing cue-induced craving. This review was aimed at conveying up-to-date information on the characteristics, evaluation, and treatment of craving. Development of objective measurement tool for evaluation of craving is needed. The effects of pharmacological treatments on 'cue-induced craving' remain to be discovered. An active effort to alleviate each type of craving is necessary to enhance and prolong a patient's abstinence.
Benzazepines ; Bupropion ; Gingiva ; Nicotine ; Quinoxalines ; Recurrence ; Smoke ; Smoking ; Smoking Cessation ; Tobacco Use Cessation Products ; Tobacco Use Disorder ; Varenicline

BACKGROUND: Varenicline is an effective smoking cessation aid. However, smokers prescribed with varenicline do not always receive varenicline for 12 weeks, as recommended. This study analyzed the subjects who received varenicline and investigated the effect of varenicline treatment duration on the success rate of 6-month smoking cessation. METHODS: This study retrospectively analyzed 78 subjects, who received varenicline, out of the 105 smokers that had visited the smoking cessation clinic after medical examination from September 2007 to December 2009. RESULTS: The subjects were all males. Twenty-two subjects (28.2%) had varenicline treatment for 12 weeks or longer; 18 subjects (23.1%) for 8~12 weeks; 22 subjects (28.2%) for 4~8 weeks; and 16 subjects (20.5%) for less than 4 weeks. The total success rate of the 6-month smoking cessation was 47.4%. The success rate of the 6-month smoking cessation was 63.6% in the group that received varenicline for 12 weeks or longer, which was higher than 41.1% of the group that early terminated the varenicline treatment (p=0.074). The period of varenicline treatment was extended for one more week, the odds ratio of the 6-month smoking cessation success increased to 1.172-folds (p=0.004; 95% confidence interval, 1.052~1.305). Adverse events occurred in 30.8% of the subjects who received varenicline, but no serious adverse events were found. CONCLUSION: If varenicline treatment period is extended, the odds ratio of the success rate for the 6-month smoking cessation increases. Therefore, an effort to improve drug compliance for varenicline in clinical practices could be helpful for the long-term success of smoking cessation.
Benzazepines ; Compliance ; Health Promotion ; Humans ; Male ; Medication Adherence ; Odds Ratio ; Quinoxalines ; Retrospective Studies ; Smoke ; Smoking ; Smoking Cessation ; Varenicline

BACKGROUND: Varenicline is known to have higher effect for smoking cessation than existing pharmacotherapies, including Bupropion and Nicotine replacement therapy, however, it can also bring about adverse effects such as problems in compliance due to the complicated dosage, side effects of high frequency, and financial burden resulted from a long term treatment. Moreover, the effect for smoking cessation with group program and non-pharmacotherapy, including financial incentives, E-mails or SMS is well known, but, the study on their combination is rare. Therefore, in the present study, we tried to evaluate two things; the effect for smoking cessation with multi-modal intervention, and the compliance of Varenicline. METHODS: From July 2008 to February 2009, we conducted the multi-modal smoking cessation program for 30 volunteers in Dankook university. This program consisted short course of Varenicline, financial incentives, E-mail and short message service. RESULTS: The continuous abstinence rate for weeks 9 throught 12 was 76.7% and for weeks 9 through 24 was 43.3%. Multivariate analysis revealed that duration of Varenicline treatment was significant factor affecting 12-week continuous abstinence rate. The average duration of Varenicline treatment was 17.1 (+/-10.8) days and 54.0% took Varenicline as directed. The most common adverse events were nausea (40.0%) and insomnia (23.3%). CONCLUSION: Multi-modal intervention (short course of Varenicline, financial incentive, E-mail and short message service) was effective for smoking cessation with high continuous abstinence rates in a university. We suggest multi-modal intervention because compliance of Varenicline seems to be low in real setting.
Benzazepines ; Bupropion ; Compliance ; Electronic Mail ; Motivation ; Multivariate Analysis ; Nausea ; Nicotine ; Quinoxalines ; Sleep Initiation and Maintenance Disorders ; Smoke ; Smoking ; Smoking Cessation ; Text Messaging ; Varenicline

BACKGROUND: Varenicline is known to have higher effect for smoking cessation than existing pharmacotherapies, including Bupropion and Nicotine replacement therapy, however, it can also bring about adverse effects such as problems in compliance due to the complicated dosage, side effects of high frequency, and financial burden resulted from a long term treatment. Moreover, the effect for smoking cessation with group program and non-pharmacotherapy, including financial incentives, E-mails or SMS is well known, but, the study on their combination is rare. Therefore, in the present study, we tried to evaluate two things; the effect for smoking cessation with multi-modal intervention, and the compliance of Varenicline. METHODS: From July 2008 to February 2009, we conducted the multi-modal smoking cessation program for 30 volunteers in Dankook university. This program consisted short course of Varenicline, financial incentives, E-mail and short message service. RESULTS: The continuous abstinence rate for weeks 9 throught 12 was 76.7% and for weeks 9 through 24 was 43.3%. Multivariate analysis revealed that duration of Varenicline treatment was significant factor affecting 12-week continuous abstinence rate. The average duration of Varenicline treatment was 17.1 (+/-10.8) days and 54.0% took Varenicline as directed. The most common adverse events were nausea (40.0%) and insomnia (23.3%). CONCLUSION: Multi-modal intervention (short course of Varenicline, financial incentive, E-mail and short message service) was effective for smoking cessation with high continuous abstinence rates in a university. We suggest multi-modal intervention because compliance of Varenicline seems to be low in real setting.
Benzazepines ; Bupropion ; Compliance ; Electronic Mail ; Motivation ; Multivariate Analysis ; Nausea ; Nicotine ; Quinoxalines ; Sleep Initiation and Maintenance Disorders ; Smoke ; Smoking ; Smoking Cessation ; Text Messaging ; Varenicline

OBJECTIVETo evaluate the effectiveness of Varenicline for smoking cessation in a community-based smoking-cessation-clinic (SCC) in Chinese smokers.

METHODSA prospective observational study was conducted in Beijing, China. 799 smokers (762 men and 37 women) were assessed on data gathered from structured questionnaires at baseline and follow up programs at 1, 3 and 6 months. Trained physician counselors provided free individual counseling and follow-up interviews with brief counseling for all the subjects. 272 subjects were additionally prescribed Varenicline according to their own choice and reported data were compared to those without Varenicline. Outcomes were self-reported, regarding the 7-day point prevalence on abstinence rate and continuous abstinence rates at 1, 3 and 6 month follow-up periods.

RESULTSAt 6-month and by intention-to-treat, the 7-day point prevalence on abstinence rate with Varenicline and counseling, was significantly higher than the group with counseling only (34.6% versus 23.1%; OR = 1.75, 95% CI: 1.27-2.42;P < 0.001). The 3-month continuous abstinence rate at 6 month was higher in the group with Varenicline(31.3% versus 18.2% ;OR = 2.04, 95% CI:1.46-2.86;P < 0.001). Varenicline also showed better outcomes at 1 and 3 month follow-up.

CONCLUSIONVarenicline prescription in the smoking cessation clinic appeared to be effective that doubled the rates of quitting among Chinese smokers in the practice at a community-based SCC.

Benzazepines ; therapeutic use ; China ; Counseling ; Female ; Humans ; Male ; Nicotinic Agonists ; therapeutic use ; Prospective Studies ; Quinoxalines ; therapeutic use ; Smoking Cessation ; Tobacco Use Disorder ; therapy ; Varenicline